WO2023067450 - COMPOSITIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSE TO SARS-COV2
National phase entry is expected:
Publication Number
WO/2023/067450
Publication Date
27.04.2023
International Application No.
PCT/IB2022/059870
International Filing Date
14.10.2022
Title **
[English]
COMPOSITIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSE TO SARS-COV2
[French]
COMPOSITIONS ET MÉTHODES POUR AMÉLIORER LA RÉPONSE IMMUNITAIRE CONTRE LE SARS-COV2
Applicants **
GLAXOSMITHKLINE BIOLOGICALS SA
Rue de l'Institut 89
B-1330 Rixensart, BE
Inventors
BACIGALUPE, Rodrigo
Rue de l'Institut 89
B-1330 Rixensart, BE
DEL CORTONA, Andrea
Rue de l'Institut 89
B-1330 Rixensart, BE
DELAHAYE, Nicolas Frederic
1400 Shady Grove Road
Rockville, Maryland 20850, US
LAMBERT, Christophe
Rue de l'Institut 89
B-1330 Rixensart, BE
WIZEL, Benjamin
14200 Shady Grove Road
Rockville, Maryland 20850, US
Priority Data
63/257,663
20.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1527 | |
| EPO | Filing, Examination | 7943 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 6310 |
Total: 16946 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure provides compositions comprising at least one bacterial cell that expresses at least one SARS-CoV2 microbiota-derived cross-reactive antigen (SARS-CoV2 mCRAg). The present disclosure provides specific SARS-CoV2 mCRAgs, and the bacterial cells that express the polypeptides that comprise the SARS-CoV2 mCRAgs and compositions thereof. The present specification provides methods for screening for SARS-CoV2 mCRAgs. Further, the present disclosure also comprises prevention methods, treatment methods, pharmaceutical and nutraceutical compositions and kits, and vaccines that comprise or utilize the SARS-CoV2 mCRAgs provided herein.[French]
La présente invention concerne des compositions comprenant au moins une cellule bactérienne qui exprime au moins un antigène à réactivité croisée issu du microbiote (mCRAg) du SARS-CoV2. La présente invention concerne des mCRAg du SARS-CoV2 spécifiques et les cellules bactériennes qui expriment les polypeptides qui comprennent ces mCRAg du SARS-CoV2 et des compositions de ceux-ci. La présente invention concerne des méthodes de dépistage de mCRAg du SARS-CoV2. En outre, la présente invention concerne également des méthodes de prévention, des méthodes de traitement, des compositions pharmaceutiques et nutraceutiques et des kits, ainsi que des vaccins qui comprennent les mCRAG du SARS-CoV2 selon l'invention ou font appel à ceux-ci.